Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems
Authors:
- Csilla BartosCBCsilla Bartos
- Rita AmbrusRita Ambrus
- Anita KovácsAKAnita Kovács
- Róbert GáspárRGRóbert Gáspár
- Anita Sztojkov-IvanovASAnita Sztojkov-Ivanov
- Árpád MárkiÁMÁrpád Márki
- Tamás JanákyTJTamás Janáky
- Ferenc TömösiFTFerenc Tömösi
- Gábor KecskemétiGKGábor Kecskeméti
- Piroska Szabó-RévészPSPiroska Szabó-Révész
Open Access
Abstract
The aim of this article was to study the trans-epithelial absorption to reach the blood and to target the brain by axonal transport using nasal formulations with nanonized meloxicam (nano MEL spray) and its salt form known as meloxicam potassium monohydrate (MELP spray). The physicochemical properties and the mucoadhesivity of nasal formulations were controlled. In vitro and in vivo studies were carried out. These forms were first investigated in “nose-to-brain” relation. It was found that the in vitro study and in vivo study did not show any significant correlation. In vitro experiments demonstrated faster dissolution rate and higher diffusion of MELP from the spray compared with the nano MEL spray. The administration of the nano MEL spray resulted in faster absorption and constant plasma concentration of the drug after five minutes of administration as compared to MELP. The axonal transport of the drug was justified. MEL appeared in the brain tissues after the first five minutes of administration in the case of both spray forms, but its amount was too small in comparison with the total plasma concentration. The application of the nano MEL spray resulted in the same AUC in the brain as the intravenous injection. The “nose-to-blood” results predicted the nasal applicability of MEL and MELP in pain management. The “nose-to-brain” pathway requires further study.Keywords
This publication has 32 references indexed in Scilit:
- Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targetingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Physicochemical and physiological considerations for efficient nose-to-brain targetingExpert Opinion on Drug Delivery, 2011
- State of the art of nanocrystals – Special features, production, nanotoxicology aspects and intracellular deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Intranasal fentanyl for pain control: current status with a focus on patient considerationsPatient Preference and Adherence, 2011
- Preparation of pH-sensitive beads for NSAID using three-component gel systemsJournal of Pharmaceutical Sciences, 2009
- Intranasal Delivery of Human β-Amyloid Peptide in Rats: Effective Brain TargetingCellular and Molecular Neurobiology, 2009
- Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissueEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Manufacture of High-Purity Meloxicam via Its Novel Potassium Salt MonohydrateOrganic Process Research & Development, 2009
- Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) modelsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Correlation between the release characteristics of theophylline and the free volume of polyvinylpyrrolidoneEuropean Journal of Pharmaceutical Sciences, 2005